Ronald Vigo Vigo, MD
Nephrology · Anasco, PRNPI 1326356395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,677 of the $7,526 with a category attached, or 88.7%. It is spread thinly across 32 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,007 and has fallen 98.8% since, to $25 in 2025. Among nephrology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$837
- Amgen$772
- Biomerieux Inc$725
- OPKO Pharmaceuticals, LLC$515
- Mallinckrodt Hospital Products Inc.$449
- plus $3K from 26 others
What the payments were for
- Consulting fees$72510%
- Food & beverage$6,67789%
- Education$1242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $1,056 |
| Otsuka America Pharmaceutical, Inc. | 31 | $837 |
| Amgen(2 entities) | 35 | $772 |
| Biomerieux Inc | 1 | $725 |
| OPKO Pharmaceuticals, LLC | 25 | $515 |
| Mallinckrodt Hospital Products Inc. | 20 | $449 |
| Abbott | 21 | $425 |
| Amarin Pharma, Inc. | 16 | $285 |
| Novartis | 14 | $272 |
| Novo Nordisk | 12 | $230 |
| Medtronic | 3 | $200 |
| Lilly USA, LLC | 8 | $168 |
| GSK | 8 | $164 |
| Travere Therapeutics, Inc. | 6 | $161 |
| Vifor Pharma, Inc. | 8 | $156 |
| Aurinia Pharma U.S., Inc. | 6 | $153 |
| Bayer | 8 | $149 |
| ANI Pharmaceuticals, Inc. | 4 | $126 |
| Bard Peripheral Vascular, Inc. | 1 | $88 |
| Calliditas Therapeutics US Inc. | 3 | $80 |
| Mallinckrodt Enterprises LLC | 3 | $70 |
| Ardelyx, Inc. | 3 | $65 |
| Boehringer Ingelheim | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| La Jolla Pharmaceutical Company | 2 | $38 |
| Akebia Therapeutics Inc | 2 | $37 |
| Johnson & Johnson | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$363
- COREVALVE EVOLUT R$163
- JYNARQUE$120
- Parsabiv$120
How this compares
$7,526 in reported general payments places this provider in the 90th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 30 | $16,282 |
| MounjaroTirzepatide | 13 | $16,067 |
| DapagliflozinDapagliflozin Propanediol | 19 | $5,463 |
| SynthroidLevothyroxine Sodium | 31 | $1,965 |
| Losartan Potassium | 196 | $1,354 |
| Atorvastatin Calcium | 155 | $1,067 |
| Clonazepam | 81 | $995 |
| Nifedipine ErNifedipine | 60 | $966 |
| Humulin NInsulin Nph Human Isophane | 12 | $816 |
| Levothyroxine Sodium | 100 | $806 |
| Rosuvastatin Calcium | 103 | $748 |
| Tamsulosin Hcl | 68 | $734 |
| Bumetanide | 33 | $729 |
| Amlodipine Besylate | 106 | $619 |
| Bupropion XlBupropion Hcl | 24 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Humulin N | $168 | $16,88325 claims |
| Boehringer IngelheimJardiance | $65 | $16,28230 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $126 | $43817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Anasco
- Eddie Rodriguez CastroToa Baja$591K
- William Hurtado-SantiagoMayaguez$191K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
- Stephanie Colon-LopezBayamon$13K
- Pedro ColtonSanturce$12K
- Rafael Burgos CalderonBayamon$12K
- Angel Rivera SantosPonce$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.